Yang Pan, Li Jing, Song Zhangyong, Chen Bin, Li Shizhu
Postdoctoral Research Station, Guangzhou Bay Area Institute of Biomedicine, Guangzhou, Guangdong 510000, China.
School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan 646000, China.
Chin Med J (Engl). 2025 Sep 5;138(17):2102-2115. doi: 10.1097/CM9.0000000000003626. Epub 2025 Aug 4.
Antibiotic-resistant (AR) bacterial wound infections (WIs) impose major burdens on healthcare systems, exacerbated by ineffective therapies and stalled antibiotic development. Phage therapy and phage-derived enzymes have gained traction as potent alternatives, leveraging targeted bactericidal mechanisms to combat AR pathogens. In this review, we summarised the antimicrobial mechanisms of both phage therapy and phage-derived enzymes as antimicrobial therapy, and outlined recent advances in their use for in vitro , in vivo and clinical applications for WI management. In addition, we also highlights recent advancements in their development, driven by genetic engineering, chemical modifications, and artificial intelligence. Finally, we identified the potential barriers and challenges they may encounter in clinical practice and the corresponding strategies to address these issues. The entire review gives us a comprehensive understanding of the latest advances in phages and their derivative enzyme therapies for treating WIs, in the hope that research in this field will continue to improve and innovate, accelerating the transition from the laboratory to application at the bedside and ultimately improving the efficacy of treatment for AR bacterial WIs.
抗生素耐药（AR）细菌伤口感染（WI）给医疗系统带来了重大负担，无效的治疗方法和停滞不前的抗生素研发使这一负担更加沉重。噬菌体疗法和噬菌体衍生酶作为有效的替代方法受到关注，它们利用靶向杀菌机制对抗AR病原体。在本综述中，我们总结了噬菌体疗法和噬菌体衍生酶作为抗菌疗法的抗菌机制，并概述了它们在体外、体内及临床应用于伤口感染管理方面的最新进展。此外，我们还强调了由基因工程、化学修饰和人工智能推动的它们在开发方面的最新进展。最后，我们确定了它们在临床实践中可能遇到的潜在障碍和挑战以及应对这些问题的相应策略。整个综述使我们全面了解了噬菌体及其衍生酶疗法在治疗伤口感染方面的最新进展，希望该领域的研究将不断改进和创新，加速从实验室到床边应用的转变，并最终提高AR细菌性伤口感染的治疗效果。
